Ultragenyx sells PRV for $210M and still has another to monetize

Summary

Ultragenyx Pharmaceutical sold a priority review voucher to an undisclosed buyer for $210 million, representing one of the highest PRV sales this year. The company retains another voucher available for future monetization.